Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Celldex Therapeutics, Inc. or AbCellera Biologics Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Celldex Therapeutics, Inc. and AbCellera Biologics Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Celldex Therapeutics, Inc. and AbCellera Biologics Inc.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Latest Biotechnology and Celldex Therapeutics, Inc., AbCellera Biologics Inc. Stock News

As of July 30, 2026, Celldex Therapeutics, Inc. had a $3.0 billion market capitalization, compared to the Biotechnology median of $251.9 million. Celldex Therapeutics, Inc.’s stock is up 40.1% in 2026, up 7.9% in the previous five trading days and up 75.33% in the past year.

Currently, Celldex Therapeutics, Inc. does not have a price-earnings ratio. Celldex Therapeutics, Inc.’s trailing 12-month revenue is $0.9 million with a % net profit margin. As of July 30, 2026, Celldex Therapeutics, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-4.352 per share for the current fiscal year. Celldex Therapeutics, Inc. does not currently pay a dividend.

As of July 30, 2026, AbCellera Biologics Inc. had a $1.7 billion market cap, putting it in the 52nd percentile of all stocks. AbCellera Biologics Inc.’s stock is up 67% in 2026, up 7.5% in the previous five trading days and up 21.32% in the past year.

Currently, AbCellera Biologics Inc. does not have a price-earnings ratio. AbCellera Biologics Inc.’s trailing 12-month revenue is $79.2 million with a -181.7% net profit margin. Year-over-year quarterly sales growth most recently was 97.6%. Analysts expect adjusted earnings to reach $-0.650 per share for the current fiscal year. AbCellera Biologics Inc. does not currently pay a dividend.

How We Compare Celldex Therapeutics, Inc. and AbCellera Biologics Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Celldex Therapeutics, Inc. and AbCellera Biologics Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Celldex Therapeutics, Inc. and AbCellera Biologics Inc. Stock Value Grades

Company	Ticker	Value
Celldex Therapeutics, Inc.	CLDX	na
AbCellera Biologics Inc.	ABCL	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Celldex Therapeutics, Inc. does not have a meaningful Value Score. AbCellera Biologics Inc. has a Value Score of 20, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Celldex Therapeutics, Inc. or AbCellera Biologics Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Celldex Therapeutics, Inc. or AbCellera Biologics Inc. is the better investment when it comes to value.

Celldex Therapeutics, Inc. and AbCellera Biologics Inc. Growth Grades

Company	Ticker	Growth
Celldex Therapeutics, Inc.	CLDX	F
AbCellera Biologics Inc.	ABCL	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Celldex Therapeutics, Inc. has a Growth Score of 3, which is Very Weak. AbCellera Biologics Inc. has a Growth Score of 10, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither Celldex Therapeutics, Inc. or AbCellera Biologics Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Celldex Therapeutics, Inc. or AbCellera Biologics Inc. is the better investment when it comes to sustainable growth.

Celldex Therapeutics, Inc. and AbCellera Biologics Inc.’s Quality Grades

Company	Ticker	Quality
Celldex Therapeutics, Inc.	CLDX	F
AbCellera Biologics Inc.	ABCL	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Celldex Therapeutics, Inc. has a Quality Score of 19, which is Very Weak. AbCellera Biologics Inc. has a Quality Score of 22, which is Weak.

The Quality Stock Winner: No Clear Winner

Neither Celldex Therapeutics, Inc. or AbCellera Biologics Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Celldex Therapeutics, Inc. or AbCellera Biologics Inc. is the better investment when it comes to quality.

Other Celldex Therapeutics, Inc. and AbCellera Biologics Inc. Grades

In addition to Growth, Value and Quality, A+ Investor also provides grades for Momentum and Estimate Revisions.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Celldex Therapeutics, Inc. and AbCellera Biologics Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Celldex Therapeutics, Inc. or AbCellera Biologics Inc. Stock?

Overall, Celldex Therapeutics, Inc. stock has a Value Score of , Growth Score of 3 and Quality Score of 19.

AbCellera Biologics Inc. stock has a Value Score of 20, Growth Score of 10 and Quality Score of 22.

Comparing Celldex Therapeutics, Inc. and AbCellera Biologics Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.